Place your advertisements here
 

Release Date: October 15, 2009
Expiration Date: October 15, 2010

KNOWLEDGE GAP ADDRESSED

Medication non-compliance for patients with epilepsy has been recognized as a significant problem for many years (Cramer et al., 2002; Hayes et al., 2007). The very significant risks associated with failure to take epilepsy medicines has been made very clear by a recent report (Faught et al., 2008) that demonstrated a significant risk for injury and death during periods of noncompliance. For reasons of patient well being and safety, physicians must be better able to recognize non-compliance and its associated risks so they can develop strategies to prevent this very significant problem.

ACKNOWLEDGMENT

This program is supported by an educational grant from GlaxoSmithKline

LEARNING OBJECTIVES

  • To teach healthcare providers how to explain to patients the importance of taking epilepsy medications as prescribed, including obtaining appropriate refills. “Medications don’t work unless patients take them.”
  • To teach healthcare providers how to apply medication compliance and persistence skills to help patients evaluate daily compliance with their medication regimen and obtaining refills.
  • To teach healthcare providers how to evaluate patients' medication taking in relation to seizures and adverse effects

TARGET AUDIENCE

Epileptologists, general neurologists, nurses, pharmacists and other healthcare professionals involved in the care of patients with epilepsy.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Epilepsy Society (AES) and the Epilepsy Therapy Project. The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

The American Epilepsy Society designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PLANNING COMMITTEE

Edward H. Bertram, III, M.D.
University of Virginia Health Science Center

Joyce A. Cramer, B.S.
President, Epilepsy Therapy Project

Robert Fisher, M.D., Ph.D.
Editor, www.epilepsy.com

Joseph Sirven, M.D.,
Co-editor, www.epilepsy.com

POLICY ON DISCLOSURES

It is the policy of the AES to make disclosures of financial relationships of faculty, planners, and staff involved in the development of educational content transparent to learners. All faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. AES carefully reviews reported conflicts of interest (COI) and resolves those conflicts by having an independent reviewer from the Council on Education validate the content of all presentations for fair balance, scientific objectivity, and the absence of commercial bias. The American Epilepsy Society adheres to the ACCME’s Essential Areas and Elements regarding industry support of continuing medical education; disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.

DISCLAIMER

Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.

FACULTY DISCLOSURES

Joyce A. Cramer, B.S.: Consulting/Advisory Board: Bial, Eisai, Cyberonics, Medtronic, Ortho-McNeil, Pfizer, Sepracor, UCB; Salary: Epilepsy Therapy Project

EDITORIAL REVIEWERS

Robert Fisher, M.D., Ph.D.: Intellectual Property/Patent Holder: NeuroVista, IntelliVision; Consulting/Advisory Board: Jazz Pharmaceuticals; SONY
Joseph Sirven, M.D.: Contracted research: Neuropace; Honoraria: UCB Pharma
Edward H. Bertram, III, M.D.: has indicated he has nothing to disclose.

CME REVIEWER

Fred A. Lado, M.D., Ph.D.: Consulting/Advisory Board: Accorda Therapuetics; Stock Ownership: Cree, Schlumberger

LEARN MORE

Go here.

Back to top